| Document Date: 2014-06-17 10:21:20
Open Document File Size: 120,96 KBShare Result on Facebook
City La Jolla / Newcastle / Oxford / / Company e-Therapeutics plc / CommStrat Group / / Country United States / United Kingdom / / / Event Company Listing Change / FDA Phase / / Facility UC San Diego Moores Cancer Center / College Hill Melanie Toyne Sewell / / IndustryTerm chemical biology / biotechnology / / MedicalCondition high-grade gliomas / secondary brain cancers / cancer / brain metastases / primary brain cancer / tumour / brain cancers / gliomas / advanced solid tumours / primary malignant brain tumours / secondary brain cancer / brain cancer / primary malignant brain tumour / brain tumour / comprehensive cancer / disorders / tumours / / MedicalTreatment radiation / / Organization National Cancer Institute / American Brain Tumor Association / UC San Diego Moores Cancer Center / / Person Ted Agne / Stephen Self / Santosh Kesari / Malcolm Young / Duncan Monteith / Fred Walsh / Rebecca Caygill / Daniel Elger / Stefanie Bacher / / / Position investigator / Professor / Director / Development / director of neuro-oncology / Development Director / / Product ETS2101 / / ProvinceOrState California / / Technology pharmacokinetics / radiation / drug discovery / biotechnology / / URL www.panmure.com / www.cancer.ucsd.edu / www.etherapeutics.co.uk / www.kesarilab.ucsd.edu/Pages/default.aspx / /
SocialTag |
e-Therapeutics provides update on ETS2101 phase I trial in brain cancer No serious drug-related adverse events after five dose escalation steps; patients to be enrolled at higher dose levels Oxford and Newcastle, UK, 7 J